Condition: Stargardt Disease · Stargardt Macular Degeneration · Stargardt Macular Dystrophy · Sponsor: Splice Bio
This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This is a multicenter study which will enroll approximately 57 subjects, followed up over a 96 week period post treatment after a single administration of SB-007.
This description comes directly from the study's public registry record.
SpliceBio · +34 934 02 04 56 · clinicaltrials@splice.bio
Always discuss trial participation with your own doctor first.
| UCHealth Sue Anschutz-Rodgers Eye Center, | Aurora, Colorado, United States | Recruiting |
| Bascom Palmer Eye Institute | Miami, Florida, United States | Recruiting |
| Massachusetts Eye and Ear Infirmary | Boston, Massachusetts, United States | Recruiting |
| Oregon Health & Science University | Portland, Oregon, United States | Recruiting |
| Retina Foundation of the Southwest | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06942572